Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Lantheus
LNTH
5
Halozyme Therapeutics
HALO
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Cash, cash equivalents and short term investments | -22.07%83.62M | -22.07%83.62M | -24.55%93.43M | 9.74%104.54M | 29.03%114.21M | 11.70%107.3M | 11.70%107.3M | 18.62%123.82M | -15.99%95.26M | -25.21%88.52M |
-Cash and cash equivalents | 36.45%21.35M | 36.45%21.35M | 2.72%33.5M | -34.41%26.77M | -7.55%24.69M | -42.51%15.65M | -42.51%15.65M | 13.24%32.62M | 0.48%40.81M | -67.63%26.71M |
-Short-term investments | -32.06%62.27M | -32.06%62.27M | -34.30%59.92M | 42.84%77.77M | 44.84%89.52M | 33.13%91.65M | 33.13%91.65M | 20.67%91.2M | -25.18%54.45M | 72.47%61.81M |
Other current assets | -17.68%2.64M | -17.68%2.64M | 64.53%4.26M | -1.70%2.9M | 16.77%2.1M | 25.37%3.21M | 25.37%3.21M | -11.08%2.59M | -15.48%2.95M | 26.03%1.8M |
Total current assets | -21.94%86.26M | -21.94%86.26M | -22.72%97.69M | 9.40%107.44M | 28.78%116.31M | 12.05%110.51M | 12.05%110.51M | 17.81%126.41M | -15.97%98.21M | -24.60%90.32M |
Non current assets | ||||||||||
Investments and advances | -81.54%5.02M | -81.54%5.02M | --0 | --0 | --3.9M | 744.80%27.19M | 744.80%27.19M | 1,223.09%26.36M | --0 | --0 |
Non current deferred assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --48K |
Other non current assets | -22.91%804K | -22.91%804K | ---- | 44.86%1.04M | 44.86%1.04M | 44.86%1.04M | 44.86%1.04M | 44.86%1.04M | 0.00%720K | 0.00%720K |
Total non current assets | -79.37%5.83M | -79.37%5.83M | --0 | 44.86%1.04M | 544.14%4.95M | 616.86%28.24M | 616.86%28.24M | 910.29%27.4M | -77.06%720K | 6.67%768K |
Total assets | -33.63%92.09M | -33.63%92.09M | -36.49%97.69M | 9.66%108.48M | 33.13%121.26M | 35.28%138.74M | 35.28%138.74M | 39.82%153.81M | -17.57%98.93M | -24.41%91.08M |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Payables | 23.95%3.32M | 23.95%3.32M | -64.92%1.71M | -39.80%1.89M | -31.37%2.43M | 26.11%2.68M | 26.11%2.68M | 238.68%4.88M | 94.23%3.13M | 35.88%3.55M |
-accounts payable | 23.95%3.32M | 23.95%3.32M | -64.92%1.71M | -39.80%1.89M | -31.37%2.43M | 26.11%2.68M | 26.11%2.68M | 238.68%4.88M | 94.23%3.13M | 35.88%3.55M |
Current accrued expenses | -33.33%4.45M | -33.33%4.45M | -27.53%4.92M | -9.31%5.84M | 63.03%6.91M | 135.50%6.68M | 135.50%6.68M | 276.18%6.79M | 257.55%6.44M | 101.86%4.24M |
Current debt and capital lease obligation | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%13K | 6.25%34K |
-Current capital lease obligation | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | 0.00%13K | 6.25%34K |
Other current liabilities | 18.41%791K | 18.41%791K | 30.64%1.28M | 18,533.33%559K | 6,320.00%321K | 11,033.33%668K | 11,033.33%668K | 12,100.00%976K | -66.67%3K | -50.00%5K |
Current liabilities | -27.10%10.24M | -27.10%10.24M | -32.50%10.02M | -9.26%10.13M | 24.48%10.66M | 95.42%14.04M | 95.42%14.04M | 234.81%14.84M | 169.00%11.16M | 68.39%8.57M |
Non current liabilities | ||||||||||
Derivative product liabilities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | -75.00%1K | -83.33%1K |
Total non current liabilities | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | -75.00%1K | -83.33%1K |
Total liabilities | -27.10%10.24M | -27.10%10.24M | -32.50%10.02M | -9.27%10.13M | 24.47%10.66M | 95.37%14.04M | 95.37%14.04M | 234.59%14.84M | 168.77%11.16M | 68.21%8.57M |
Shareholders'equity | ||||||||||
Share capital | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
-common stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
-Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Retained earnings | -33.23%-205.78M | -33.23%-205.78M | -44.12%-198.25M | -53.50%-185.51M | -62.85%-171.07M | -72.15%-154.46M | -72.15%-154.46M | -76.62%-137.56M | -81.61%-120.85M | -86.18%-105.05M |
Paid-in capital | 3.12%287.59M | 3.12%287.59M | 3.31%285.81M | 36.01%283.89M | 50.00%281.62M | 50.37%278.88M | 50.37%278.88M | 50.36%276.65M | 14.21%208.73M | 9.16%187.74M |
Gains losses not affecting retained earnings | -88.73%31K | -88.73%31K | 191.80%112K | 77.31%-27K | 130.29%53K | 173.53%275K | 173.53%275K | 77.45%-122K | 66.94%-119K | -10.76%-175K |
Total stockholders'equity | -34.36%81.85M | -34.36%81.85M | -36.91%87.67M | 12.07%98.35M | 34.03%110.6M | 30.75%124.7M | 30.75%124.7M | 31.63%138.97M | -24.25%87.76M | -28.50%82.52M |
Total equity | -34.36%81.85M | -34.36%81.85M | -36.91%87.67M | 12.07%98.35M | 34.03%110.6M | 30.75%124.7M | 30.75%124.7M | 31.63%138.97M | -24.25%87.76M | -28.50%82.52M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |